U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Drug Trials Snapshots: ELUCIREM
  1. Drug Approvals and Databases

Drug Trials Snapshots: ELUCIREM

HOW TO USE THIS SNAPSHOT
The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

LIMITATIONS OF THIS SNAPSHOT
Do not rely on Snapshots to make decisions regarding medical care. Always speak to your healthcare provider about the benefits and risks of a drug.

Some of the information in this Snapshot is for presentation purposes and does not represent the approved conditions of use of this drug. Refer to the ELUCIREM Prescribing Information for all the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information).

Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable).

ELUCIREM (gadopiclenol)
(ah – LOOS – er - em)
Guerbet LLC
Approval date: September 21, 2022


DRUG TRIALS SNAPSHOT SUMMARY:

What is the drug for?

ELUCIREM is a gadolinium-based contrast agent that is used during magnetic resonance imaging (MRI) in adult and pediatric patients aged 2 years and older to detect and visualize lesions with abnormal blood supply in the brain, spine, head and neck, thorax, abdomen, pelvis, and musculoskeletal system.

How is this drug used?

ELUCIREM is injected intravenously during an MRI scan.

Who participated in the clinical trials?

The FDA approved ELUCIREM based on evidence from eight clinical trials of 1,047 patients or healthy volunteers who received at least one dose of ELUCIREM, including two pivotal trials of ELUCIREM safety and effectiveness in 551 adults. Trial 1, which enrolled patients with central nervous system (CNS) lesions, was conducted at 33 sites in 11 countries and Trial 2, which enrolled patients with lesions outside the CNS, was conducted at 33 sites in 11 countries.

What are the benefits of this drug?

For patients getting an MRI, having images taken after ELUCIREM was given in addition to images taken before ELUCIREM was given helped make some abnormalities easier to see.

Were there any differences in how well the drug worked in clinical trials among sex, race and age?

  • Sex: ELUCIREM worked similarly in males and females.
  • Race: The number of patients of races other than White was small; therefore, differences in how ELUCIREM worked among races could not be determined.
  • Age: ELUCIREM worked similarly in patients below and above 65 years of age.

What are the possible side effects?

The most common side effects were injection site discomfort (pain, warmth, or coldness), headache, nausea, dizziness, and local swelling.

Were there any differences in side effects among sex, race and age?

  • Sex: The occurrence of side effects was slightly higher in females.
  • Race: The number of patients of races other than White was small; therefore, differences in side effects among races could not be determined.
  • Age: The occurrence of side effects was similar in patients younger and older than 65 years of age.

DEMOGRAPHICS SNAPSHOT

Figure 1 summarizes how many male and female patients were enrolled in the combined clinical trials.

Figure 1. Baseline Demographics by Sex (Safety Population)

Pie chart summarizing how many male and female patients were in the clinical trial. In total, 482 (46%) male patients and 565 (54%) female patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 2 summarizes the percentage of patients by race enrolled in the combined clinical trials.

Figure 2. Baseline Demographics by Race (Safety Population)

Pie chart summarizing how many White, Black or African American, Asian, American Indian or Alaska Native, Native Hawaiian or Pacific Islander, and other patients were in the clinical trial. In total, 828 (78.9%) White patients, 25 (2.4%) Black or African American patients, 95 (9.0%) Asian patients, 48 (4.6%) American Indian or Alaska Native patients, 3 (0.3%) Native Hawaiian or Pacific Islander patients, and 51 (4.8%) Other (including not collected) patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 3 summarizes the percentage of patients by age group in the combined clinical trials.

Figure 3. Baseline Demographics by Age (Safety Population)

Pie chart summarizing how many patients by age were in the clinical trial. In total, 80 (8%) patients between 2 and 17 years of age, 697 (66%) patients between 18 and 64 years of age, and 270 (26%) patients older than 65 years of age participated in the clinical trial.

Source: Adapted from FDA Review

Figure 4 summarizes the percentage of patients by ethnicity in the combined clinical trials.

Figure 4. Baseline Demographics by Ethnicity (Safety Population)

Pie chart summarizing how many Hispanic, Not Hispanic, and other patients were in the clinical trial. In total, 144 (14%) Hispanic or Latino patients, 855 (82%) Not Hispanic or Latino patients, and 48 (4%) patients without ethnicity data participated in the clinical trial.

Source: Adapted from FDA Review

How were the trials designed?

The benefits of ELUCIREM were mainly evaluated in two confirmatory studies in 551 adults who received a single dose each. Study 1 was performed in adults with abnormalities in the brain or spinal cord. Study 2 was performed in adults with abnormalities outside the brain or spinal cord.

In each study, images of the affected body part were obtained using MRI both before and after patients received a dose of ELUCIREM. Three radiologists scored the images based on how well the abnormalities were seen. The benefit of ELUCIREM was evaluated by comparing the scores from the combined images obtained before and after ELUCIREM to the scores from the images obtained before ELUCIREM.

GLOSSARY

CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.
COMPARATOR: A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested.
EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.
PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.
SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.

PRESCRIBING INFORMATION

Back to Drug Trials Snapshots

Back to Top